Controversies in Drug Treatment of Alzheimer Disease: What is Meaningful Benefit?

Moderator: G. Michael Harper, MD, Associate Chief of Staff for Geriatrics, Palliative and Extended Care, San Francisco VA Medical Center
Two expert faculty will engage in a  point/counterpoint debate about whether cholinesterase inhibitors provide meaningful benefit.  The session will focus on 3 clinical scenarios:  To start or not? To stop or not? What about the 23 mg formulation?  

Pro
Jacobo E. Mintzer, MD, Professor of Psychiatry and Neurosciences, Co-Director of Alzheimer's
Research & Clinical Programs, Medical University of South Carolina

 

Con
Thomas E. Finucane, MD, Professor of Medicine, Johns Hopkins University